Intra-laboratory validated “TigraTest® SARS-CoV-2” — test assessing release of interferon gamma in vitro to identify peripheral blood T-lymphocytes specifically responding against SARS-CoV-2 virus antigens
Open Access
- 15 November 2022
- journal article
- research article
- Published by SPb RAACI in Russian Journal of Infection and Immunity
- Vol. 12 (4) , 701-713
Abstract
SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2), also known as 2019-nCoV (2019-Novel Coronavirus) is a strain of coronavirus from the genus Betacoronavirus, discovered in China at the end of 2019 in patients with pneumonia. Coronavirus infection COVID-19 (COrona VIrus Disease 2019) caused by coronavirus 2019 (COVID-19) has spread around the world at a very fast pace, with death toll exceeding more than 5.2 million people worldwide. Limited success in developing new drugs as well as use of existing drugs for the treatment of COVID-19 resulted in situation when the main prevention measures for a long time were based on testing and isolation of sick subjects, which started to reverse due to vaccination. Monitoring the formation of humoral and T-cell population immunity against the SARS-CoV-2 virus during the COVID-19 pandemic is a necessary element for epidemiological surveillance. ELISA-based methods are widely used to assess humoral immunity, and various test systems including ELISPOT (Enzyme-Linked ImmunoSpot) are used to analyze cellular immunity. The ELISPOT assay is a highly sensitive and specific method for quantifying individual cytokine-secreting T cells after being stimulated with a specific antigen. TigraTest SARS-CoV-2 Test assessing release of interferon gamma in vitro to detect peripheral blood T-lymphocytes that specifically respond to the SARS-CoV-2 virus antigens manufactured by GENERIUM JSC, is created on the ELISPOT platform. This study describes the procedure for laboratory validation of this test system to analyze the following parameters: specificity of antibody pair, effect of interfering substances, sensitivity and specificity, precision, stability of blood samples till isolation of target cells. The developed test system showed high diagnostic sensitivity and specificity. The specificity of TigraTest SARS-CoV-2 was 100%, the sensitivity for subjects immunized with the Gam-COVID-Vac vaccine (Sputnik V) was 91.67%, and the sensitivity in convalescent COVID-19 patients was 95.45%. At the same time, the data variability both during within and between series comparison did not exceed 25%, whereas 24-hour storage of peripheral blood samples at (1825)С after blood collection followed by isolation of target cells did not affect the test results.Keywords
This publication has 16 references indexed in Scilit:
- Common pitfalls in statistical analysis: Understanding the properties of diagnostic tests – Part 1Perspectives in Clinical Research, 2018
- The Role of Physical Stabilization in Whole Blood PreservationScientific Reports, 2016
- Effects of Blood Transportation on Human Peripheral Mononuclear Cell Yield, Phenotype and Function: Implications for Immune Cell BiobankingPLOS ONE, 2014
- Stability of 35 biochemical and immunological routine tests after 10 hours storage and transport of human whole blood at 21°CScandinavian Journal of Clinical and Laboratory Investigation, 2014
- Interferon gamma release assays: principles and practiceEnfermedades Infecciosas y Microbiología Clínica, 2010
- Standardization and Validation Issues of the ELISPOT Assay2005
- Use of Interferon-γ ELISPOT in Monitoring Immune Responses in Humans2004
- Development and Validation of a Gamma Interferon ELISPOT Assay for Quantitation of Cellular Immune Responses to Varicella-Zoster VirusClinical and Diagnostic Laboratory Immunology, 2001
- Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor VaccinesClinical and Diagnostic Laboratory Immunology, 2000
- A valid ELISPOT assay for enumeration of ex vivo, antigen-specific, IFNγ-producing T cellsJournal of Immunological Methods, 1999